// App-Quantinova.ai

P826 : FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

Researchers

Presenter

  • Austin Kulasekararaj

Principal Investigators

  • Wolfgang Freder

  • Andrew McDonald

  • Jacques Le Roux Malherbe

  • Shreyans Gandhi

  • David Collins

  • Melanie Cornpropst

  • Sylvia Dobo

  • Mary Katherine Farmer

  • Deborah Kargl

  • William Sheridan

  • Morag Griffin

  • Antonio Risitano

Medical Centers

  • BioCryst Pharmaceuticals, Inc

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • Netcare Pre

  • Medical University of Vienna, Vienna, Austria

  • University of the Free State, Bloemfontein, South Africa

  • Leeds Teaching Hospitals NHS Trust,Leeds,Verenigd Koninkrijk

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • University of the Free State,Bloemfontein,南非

  • Medical University of Vienna, Vienna, Austria

  • Bantam Pharmaceutical,Durham,Vereinigte Staaten

  • AORN Moscati,Avellino,Italy

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • Kings College Hospital NHS Foundation Trust,London,Verenigd Koninkrijk

  • Bantam Pharmaceutical,Durham,Estados Unidos

  • Bantam Pharmaceutical,Durham,Stati Uniti

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • Medical University of Vienna, Vienna, Austria

  • Leeds Teaching Hospitals, NHS Trust,Leeds,Reino Unido

  • AORN Moscati,Avellino,Italy

  • BioCryst Pharmaceuticals, Inc.,Durham,United States

  • Medical University of Vienna,Vienna,Австрия

  • Medical University of Vienna, Vienna, Austria

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Leeds Teaching Hospitals, NHS Trust,Leeds,Reino Unido

  • University of the Free State, Bloemfontein, South Africa

  • Bantam Pharmaceutical,Durham,Vereinigte Staaten

  • University of the Free State,Blo

  • AORN Moscati,Avellino,Italy

  • AORN Moscati,Avellino,Италия

  • University of the Free State,Bloemfontein,Afrique Du Sud

  • Leeds Teaching Hospitals, NHS Trust,Leeds,Reino Unido

  • Kings College Hospital NHS Foundation Trust,London,Reino Unido

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • BioCryst Pharmaceuticals,Durham,États-unis

  • Medical University of Vienna, Vienna, Austria

  • Kings College Hospital NHS Foundation Trust,London,Reino Unido

  • University of the Free State, Bloemfontein, South Africa

  • AORN Moscati,Avellino,Italy

  • Leeds Teaching Hospitals NHS Trust,Leeds,Verenigd Koninkrijk

  • Kings College Hospital NHS Foundation Trust,London,Reino Unido

  • Netcare Pretoria East Hospital,Moreleta Park,África do Sul

  • University of the Free State, Bloemfontein, South Africa

  • Leeds T

  • AORN Moscati,Avellino,Italy

  • Medical University of Vienna, Vienna, Austria

  • University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • AORN Moscati,Avellino,Italy

  • University of the Free State,Bloemfontein,Afrique Du Sud

Locations

  • United Kingdom

  • United States

  • Austria

  • South Africa

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • Complement Factor B

  • Lactate dehydrogenase

  • White Blood Cell

  • Red Blood Cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • N/A

Study Id's

  • NCT04330534

  • NCT04702568

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved